Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurological disorder therapies - NPS

Drug Profile

Research programme: neurological disorder therapies - NPS

Alternative Names: CSC 500; CSC 500-204; NPS 156; NPS 1897; NPSP 156

Latest Information Update: 24 Feb 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NPS Pharmaceuticals
  • Class
  • Mechanism of Action Glycine NMDA-associated agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued CNS disorders; Epilepsy; Neuropathic pain; Schizophrenia

Most Recent Events

  • 16 Oct 2007 Preclinical development is ongoing
  • 08 Nov 2006 Preclinical trials in Neuropathic pain in USA (unspecified route)
  • 31 Oct 2003 Preclinical trials in CNS disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top